Updated:
Transhuman Capital
Investing in hard science to solve humanity's big problems | We invest in therapeutics, medical devices, and other technologies that have the potential to...
Transhuman Capital
Investing in hard science to solve humanity's big problems | We invest in therapeutics, medical devices, and other technologies that have the potential to fundamentally improve the human condition. Our vision is a society where everyone can live a long, healthy, daring and meaningful life.
General information
Firm type
Generalist
Year founded
2014
Location
Region
North America
Country
United States
City
Ann Arbor
Corporate office
Ann Arbor, MI, United States
Frequently asked questions
Who runs investment decisions at Transhuman Capital?
No named principals—including a CEO, CIO, or managing partner—appear in public records for Transhuman Capital. The firm does not maintain a discernible LinkedIn presence, and its website does not list any leadership biographies or investment committee members. Allocators should assume that investment decision-making authority is not externally documented.
Is Transhuman Capital structured as a venture capital firm or a family office?
Transhuman Capital self-identifies as an asset manager with an early-stage, generalist strategy, placing it closer to a venture capital firm than a family office. However, without disclosed AUM, fund structures, or limited partner profiles, its exact legal and operational structure is not ascertainable from public sources.
Does Transhuman Capital participate in fund commitments or only direct deals?
The firm's stated focus on seed and venture-stage companies implies a direct investment posture, but no evidence confirms whether it also commits as a limited partner to other funds. No fund-of-funds activity, co-investment vehicles, or manager-selection mandates have been disclosed.
What investment stages does Transhuman Capital typically target?
Altss research identifies Transhuman Capital's strategy as covering seed and general venture stages. This suggests early-stage company engagement, though no specific round sizes, check sizes, or lead versus follow patterns are delineated in any available firm communication.
Which sectors does Transhuman Capital explicitly avoid?
Transhuman Capital defines its mandate as generalist, indicating no explicit sector exclusions are part of its public investment policy. Without a published portfolio or restricted-sector list, practitioners cannot confirm whether the firm has negative screens—such as on defense, tobacco, or fossil fuels—as is sometimes disclosed by peer firms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: